Molecular differences between younger versus older ER-positive and HER2-negative breast cancers
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2374-4677
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Molecular differences between younger versus older ER-positive and HER2-negative breast cancers ; volume:8 ; number:1 ; day:7 ; month:11 ; year:2022 ; pages:1-11 ; date:12.2022
npj Breast cancer ; 8, Heft 1 (7.11.2022), 1-11, 12.2022
- Creator
-
Qing, Tao
Karn, Thomas
Rozenblit, Mariya
Foldi, Julia
Marczyk, Michal
Shan, Naing Lin
Blenman, Kim
Holtrich, Uwe
Kalinsky, Kevin
Meric-Bernstam, Funda
Pusztai, Lajos
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1038/s41523-022-00492-0
- URN
-
urn:nbn:de:101:1-2023012110531296466842
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:33 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Qing, Tao
- Karn, Thomas
- Rozenblit, Mariya
- Foldi, Julia
- Marczyk, Michal
- Shan, Naing Lin
- Blenman, Kim
- Holtrich, Uwe
- Kalinsky, Kevin
- Meric-Bernstam, Funda
- Pusztai, Lajos
- SpringerLink (Online service)
Other Objects (12)
Image analysis-based identification of high risk ER-positive, HER2-negative breast cancers
Benefit of systemic therapy in MINDACT patients with small, ER-positive, HER2-negative breast cancers
Characteristics of HER2-negative breast cancers with FISH-equivocal status according to 2018 ASCO/CAP guideline
New HER2-negative breast cancer subtype responsive to anti-HER2 therapy identified
Downregulation of EphA2 stability by RNF5 limits its tumor-suppressive function in HER2-negative breast cancers
Immunotherapy for hormone receptor‒positive HER2-negative breast cancer
Serial Tumor Molecular Profiling of Newly Diagnosed HER2-Negative Breast Cancers During Chemotherapy in Combination with Angiogenesis Inhibitors
Impact of estrogen receptor expression level on response to neoadjuvant chemotherapy and prognosis in HER2-negative breast cancers
HER2-low breast cancer shows a lower immune response compared to HER2-negative cases
Classification of PR-positive and PR-negative subtypes in ER-positive and HER2-negative breast cancers based on pathway scores
Single HER2-positive tumor cells are detected in initially HER2-negative breast carcinomas using the DEPArray™–HER2-FISH workflow
EndoPredict® in early hormone receptor-positive, HER2-negative breast cancer
Image analysis-based identification of high risk ER-positive, HER2-negative breast cancers
Benefit of systemic therapy in MINDACT patients with small, ER-positive, HER2-negative breast cancers
Characteristics of HER2-negative breast cancers with FISH-equivocal status according to 2018 ASCO/CAP guideline
New HER2-negative breast cancer subtype responsive to anti-HER2 therapy identified
Downregulation of EphA2 stability by RNF5 limits its tumor-suppressive function in HER2-negative breast cancers
Immunotherapy for hormone receptor‒positive HER2-negative breast cancer
Serial Tumor Molecular Profiling of Newly Diagnosed HER2-Negative Breast Cancers During Chemotherapy in Combination with Angiogenesis Inhibitors
Impact of estrogen receptor expression level on response to neoadjuvant chemotherapy and prognosis in HER2-negative breast cancers
HER2-low breast cancer shows a lower immune response compared to HER2-negative cases
Classification of PR-positive and PR-negative subtypes in ER-positive and HER2-negative breast cancers based on pathway scores
Single HER2-positive tumor cells are detected in initially HER2-negative breast carcinomas using the DEPArray™–HER2-FISH workflow
EndoPredict® in early hormone receptor-positive, HER2-negative breast cancer
Image analysis-based identification of high risk ER-positive, HER2-negative breast cancers
Benefit of systemic therapy in MINDACT patients with small, ER-positive, HER2-negative breast cancers
Characteristics of HER2-negative breast cancers with FISH-equivocal status according to 2018 ASCO/CAP guideline
New HER2-negative breast cancer subtype responsive to anti-HER2 therapy identified
Downregulation of EphA2 stability by RNF5 limits its tumor-suppressive function in HER2-negative breast cancers
Immunotherapy for hormone receptor‒positive HER2-negative breast cancer
Serial Tumor Molecular Profiling of Newly Diagnosed HER2-Negative Breast Cancers During Chemotherapy in Combination with Angiogenesis Inhibitors
Impact of estrogen receptor expression level on response to neoadjuvant chemotherapy and prognosis in HER2-negative breast cancers
HER2-low breast cancer shows a lower immune response compared to HER2-negative cases
Classification of PR-positive and PR-negative subtypes in ER-positive and HER2-negative breast cancers based on pathway scores
Single HER2-positive tumor cells are detected in initially HER2-negative breast carcinomas using the DEPArray™–HER2-FISH workflow